巨噬细胞移动抑制因子在妇科恶性肿瘤中的表达  

Expression of Macrophage Migration Inhibitory Factor in Gynecologic Malignant Tumor

作　　者：夏晓艾[1] 何成章[1] 李莉华[2] 吕蓓[1] 浦红[1] 任金冬[2] 张振宇[1] 毛玉荣[1] 

机构地区：[1]苏州大学附属第四医院妇瘤科,江苏无锡214062 [2]苏州大学附属第四医院中心实验室,江苏无锡214062

出　　处：《苏州大学学报（医学版）》2006年第4期647-649,652,共4页Suzhou University Journal of Medical Science

摘　　要：目的观察妇科恶性肿瘤患者血清、腹腔液中巨噬细胞移动抑制因子(MIF)的表达及其与恶性肿瘤的相关性。方法选择术前未行任何治疗的妇科恶性肿瘤患者46例作为实验组(卵巢癌21例,子宫恶性肿瘤25例),良性肿瘤患者24例为对照组。ELISA法检测术前肘静脉血、术中腹腔液的MIF浓度。同时测定血清血管内皮生长因子(VEGF)及CA125浓度。结果实验组腹腔液MIF的浓度(21.98±11.27 ng/ml)与对照组(13.85±8.11 ng/ml)相比差异显著(P<0.01);而血清MIF浓度(分别为5.13±3.53 ng/ml和3.42±2.06 ng/ml)无明显差异(P>0.05)。卵巢癌患者腹腔液和血MIF的浓度(26.26±11.46 ng/ml,5.52±3.04 ng/ml)分别与良性卵巢肿瘤(11.10±6.68 ng/ml,2.92±1.90 ng/ml)相比,均有显著差异(P<0.001,P<0.01);腹腔液与血清中MIF浓度有相关(r=0.5821,P<0.01);腹腔液MIF浓度与血CA125有关联(r=0.6649,P<0.05),与血清VEGF也相关(r=0.405,P<0.05)。子宫恶性肿瘤患者腹腔液和血清MIF的浓度(18.20±8.67 ng/ml和4.68±3.24 ng/ml)与子宫肌瘤(17.24±6.32 ng/ml和2.8±2.20 ng/ml)相比,均无差异(均P>0.05)。结论卵巢癌患者腹腔液与血清均有MIF表达,而腹腔液MIF呈高表达,可能与CA125类似,主要源于肿瘤组织。MIF与VEGF可能存在互相诱导分泌的关系。Objective To investigate the expressions of macrophage migration inhibitory factor （MIF） in gynecologic malignancy tumor patients and the correlation between VEGF and CA125. Methods There were 46 patients with gynecologic malignancy tumor （including 21 cases of ovarian carcinoma, 25 cases of uterine carcinoma） as a study group, 24 patients with benign tumor as the control group. The levels of serum MIF and ascitis MIF, levels of serum VEGF and CA125 were measured by ELISA. Results The levels of ascitis MIF （21.98 ± 11.27 ng/ml） in study group was significantly higher than that in the control group（13.85 ± 8.11 ng/ml）, P 〈 0.01. But there was no difference in serum levels between the two groups （5.13 ± 3.53 ng/ml vs 3.42 ± 2.06 ng/ml）, P 〉 0.05. The MIF levels of ascitis and serum （26.26 ± 11.46 ng/ml ＆ 5.52 ± 3.04 ng/ml） in ovarian cancer were markedly higher, as compared with that in benign ovarian tumor （11.10 ± 6.68 ng/ml ＆ 2.92 ± 1.90 ng/ml） P〈 0. 001, P〈 0.01. There were a positive correlation between ascitis MIF and serum MIF in ovarian carcinoma（ r = 0. 5821, P 〈 0.01）, in which MIF level of ascitis was correlated with serum CA125 values （r = 0. 6649, P 〈 0.05）. The positive correlation was also found in ascites MIF and serum VEGF in ovarian carcinoma group（ r = 0. 405, P 〈 0.05）. Comparing with patients with myoma, the levels of ascites and serum MIF level were no significantly difference in patients with uterine carcinoma （P 〉0.05, respectively）. Conclusion The high MIF level of ascites in ovarian cancer may originate from tumor sites, which is similar to CA125. MIF could be induced to secret by VEGF, besides both factors may accelerate the progress of carcinoma together.

关 键 词：巨噬细胞移动抑制因子 血管内皮生长因子 CA125 妇科肿瘤 

分 类 号：R737.3[医药卫生—肿瘤]